与结性脊柱炎相关的CD28和CTLA4多态:在HLA-B27的背景下进行的一项研究
Kuang-Hui Yu1, Gem Huai-Chueh Wu2, Chia-Ju Yang3
1Division of Rheumatology, Allergy, and Immunology, Chang Gung University and Linkou Chang Gung Memorial Hospital, Taoyuan, Taiwan.
BMC immunology
|May 19, 2025
概括
结节性脊柱炎 (AS) 的风险与CD28和CTLA4的特定基因变异有关,特别是与HLA-B27阳性相结合时. 这些遗传因素为AS发展提供了新的见解.
科学领域:
- 免疫遗传学 免疫遗传学
- 类风湿病学 类风湿病学
- 遗传学 是一个遗传学.
背景情况:
- 结性脊柱炎 (AS) 与人类白细胞抗原 (HLA) -B27基因密切相关.
- 并非所有HLA-B27携带者都会发展AS,这表明其他遗传因素会影响疾病发病.
- 协同刺激和协同抑制的分子与AS等自身免疫性疾病有关.
研究的目的:
- 研究同刺激/抑制分子中单核酸多态 (SNP) 与AS之间的关联.
- 为了确定除了HLA-B27.2之外的AS病原体的其他遗传因素.
- 分析特定SNP与HLA-B27阳性在AS风险中的相互作用.
主要方法:
- 招募了32名AS患者和32名对照.
- 从全血中提取的DNA用于PCR放大CTLA4,CD28和PDCD1促进体区域.
- 利用奇方位和费舍尔的精确测试,以及后勤回归,分析基因型和等位基因分布及其与AS的关联.
主要成果:
- 在CD28 (rs201801072) 和CTLA4 (rs11571319) 中,特定的SNP与AS有显著的关联.
- 这些SNP (CD28 rs201801072和CTLA4 rs11571319) 显示与AS的独立关联.
- 在这些SNP和HLA-B27阳性之间发现了显著的积极相互作用,大大增加了AS风险. 携带HLA-B27的患者具有非常高的AS风险 (OR=65.0).
结论:
- 在AS患者中特定基因的高频率表明它们参与AS病变发生.
- 这些发现提供了对AS背后的遗传机制的新见解.
- 针对共刺激/抑制途径可能为AS提供新的治疗策略.
相关概念视频
T Cell Activation and Clonal Selection
622
T cells are integral to our adaptive immune system, recognizing and effectively responding to foreign antigens. T cell activation and clonal selection are pivotal in orchestrating this immune response. This article elucidates these mechanisms, detailing the roles of cluster of differentiation (CD) markers, major histocompatibility complex (MHC) molecules, costimulatory signals, and the process of clonal selection.
Naive T cells that have not yet encountered an antigen express two primary CD...
Naive T cells that have not yet encountered an antigen express two primary CD...
622
Genome-wide Association Studies-GWAS
12.3K
Genome-wide association studies or GWAS are used to identify whether common SNPs are associated with certain diseases. Suppose specific SNPs are more frequently observed in individuals with a particular disease than those without the disease. In that case, those SNPs are said to be associated with the disease. Chi-square analysis is performed to check the probability of the allele likely to be associated with the disease.
GWAS does not require the identification of the target gene involved in...
GWAS does not require the identification of the target gene involved in...
12.3K
Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF
107
Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab...
107


